Provided by Tiger Trade Technology Pte. Ltd.

AIM ImmunoTech Inc.

0.2332
+0.00351.52%
Post-market: 0.2284-0.0048-2.06%19:57 EDT
Volume:9.03M
Turnover:2.09M
Market Cap:7.10M
PE:-0.06
High:0.2370
Open:0.2290
Low:0.2267
Close:0.2297
52wk High:2.98
52wk Low:0.1901
Shares:30.44M
Float Shares:30.44M
Volume Ratio:0.54
T/O Rate:29.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9303
EPS(LYR):-30.8884
ROE:-2382.30%
ROA:-82.58%
PB:0.92
PE(LYR):-0.01

Loading ...

AIM ImmunoTech CEO Urges Biodefense Military Integration

TIPRANKS
·
Aug 11

AIM ImmunoTech Q2 EPS $-0.43

THOMSON REUTERS
·
Aug 10

Press Release: AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen(R) Toward Planned Phase 3 Development in Pancreatic Cancer

Dow Jones
·
Aug 10

AIM ImmunoTech Q2 FY26 Net Loss Widens 35.6% to USD 3.79 Million

Reuters
·
Aug 08

AIM ImmunoTech Signs Manufacturing Pact with Sterling Pharma, Cost Seen at $1.5 Million

Reuters
·
Aug 07

AIM ImmunoTech Expands Manufacturing for Ampligen Clinical Supply

TIPRANKS
·
Aug 07

AIM ImmunoTech - Enters Proposal Agreement with Sterling Pharma Solutions on July 31, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 07

Hargreave Hale AIM VCT Cuts Share Count With Buyback and Cancellation

TIPRANKS
·
Aug 05

IQE Director Bastani Sells 500,000 Shares on AIM

TIPRANKS
·
Aug 05

Puma AIM VCT Plans £20 Million Fundraise with New 2026 Share Offer

TIPRANKS
·
Aug 04

AIM ImmunoTech - Duripanc Primary Endpoint Analysis to Begin December 2026; Topline Results Expected Q1 2027

THOMSON REUTERS
·
Aug 03

AIM ImmunoTech Completes Last Dosing in Phase 2 Duripanc Trial of Ampligen Plus AstraZeneca Imfinzi in Metastatic Pancreatic Cancer

Reuters
·
Aug 03

AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point

GlobeNewswire
·
Aug 03

Unicorn AIM VCT Updates Share Capital and Voting Rights

TIPRANKS
·
Aug 03

Restore cancels 120,000 shares after latest buyback on AIM

TIPRANKS
·
Aug 03

AIM Vaccine Advances Serum-Free Rabies Shot Toward China Market Approval

TIPRANKS
·
Aug 03

Komatsu Unit Partners with AIM for US Autonomous Construction

MT Newswires Live
·
Jul 31

Boku adjusts voting share base after latest AIM buyback

TIPRANKS
·
Jul 30

Hargreave Hale AIM VCT delivers resilient Q3 NAV growth amid volatile markets

TIPRANKS
·
Jul 30

Puma AIM VCT Shareholders Approve All Resolutions at 2026 AGM

TIPRANKS
·
Jul 29